Compare HAFN & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HAFN | ICUI |
|---|---|---|
| Founded | 2012 | 1984 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 3.6B |
| IPO Year | N/A | 1992 |
| Metric | HAFN | ICUI |
|---|---|---|
| Price | $5.75 | $153.17 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $179.50 |
| AVG Volume (30 Days) | ★ 1.1M | 212.9K |
| Earning Date | 02-26-2026 | 02-26-2026 |
| Dividend Yield | ★ 6.95% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | $2,221,808,000.00 | ★ $2,320,363,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.30 | N/A |
| P/E Ratio | $9.31 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.61 | $107.00 |
| 52 Week High | $6.64 | $175.51 |
| Indicator | HAFN | ICUI |
|---|---|---|
| Relative Strength Index (RSI) | 52.10 | 55.10 |
| Support Level | $5.63 | $152.38 |
| Resistance Level | $5.97 | $160.29 |
| Average True Range (ATR) | 0.13 | 5.38 |
| MACD | 0.03 | 0.32 |
| Stochastic Oscillator | 61.31 | 67.83 |
Hafnia Ltd is one of the tanker owners, transporting oil, oil products and chemicals for national and international oil companies, chemical companies, as well as trading and utility companies. As owners and operators of around 200 vessels, It offers a fully integrated shipping platform, including technical management, commercial and chartering services, pool management, and a large-scale bunker procurement desk.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.